Welcome to our dedicated page for Adaptimmune Therapeutics plc American Depositary Shares news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics plc American Depositary Shares stock.
Adaptimmune Therapeutics plc (NASDAQ: ADAP) is a clinical-stage biopharmaceutical company focused on the design, development, and delivery of T-cell therapies to treat cancer. Established in 2008, Adaptimmune has grown from a private entity to one of the top biopharmaceutical IPOs in 2015, and its U.S. operations are headquartered in Philadelphia, PA. Using its proprietary T-cell receptor (TCR) platform, Adaptimmune engineers T-cells to target and destroy cancer cells. This innovative approach has led to the development of a robust pipeline of immuno-oncology product candidates primarily aimed at solid tumors.
The company’s leading programs include afami-cel and lete-cel, both engineered T-cell therapies targeting specific cancer antigens. Afami-cel, targeting MAGE-A4, has shown promising results in treating advanced synovial sarcoma, with the U.S. FDA accepting its Biologics License Application (BLA) for priority review. The anticipated approval and commercial launch of afami-cel in 2024 will mark a significant milestone for Adaptimmune, potentially making it the first engineered T-cell therapy for solid tumors available to patients. Lete-cel, targeting NY-ESO-1, is being evaluated for synovial sarcoma and myxoid round cell liposarcoma (MRCLS) in the pivotal IGNYTE-ESO trial. Preliminary results indicate a 40% response rate, meeting the primary efficacy endpoint.
Adaptimmune has formed strategic partnerships to advance its pipeline and enhance its manufacturing capabilities. Recent collaborations include agreements with Galapagos to develop next-generation TCR therapies and a $125 million debt financing deal with Hercules Capital, strengthening its financial position.
In addition to its lead programs, Adaptimmune is advancing a broad clinical and preclinical pipeline, including ADP-A2M4CD8 (uza-cel), targeting a range of solid tumors, and several other next-generation and allogeneic T-cell therapies. The company continues to invest in research and development, with plans to expand its platform and address additional cancer indications.
The company’s commitment to transforming cancer treatment is underpinned by a strategy of bringing novel therapies to market efficiently. With over $300 million in funding and strategic plans extending into 2026, Adaptimmune is well-positioned to achieve significant milestones and make substantial impacts in the field of oncology.
Adaptimmune Therapeutics has appointed Cintia Piccina as Chief Commercial Officer, effective January 31, 2022. Piccina brings over 20 years of experience in the biopharmaceutical industry, particularly in cell and gene therapy. Her previous roles include Head of Commercial at 2Seventy Bio and SVP at bluebird bio, where she led the launch of Abecma, the first cell therapy for multiple myeloma. This leadership change aims to bolster Adaptimmune's commercial strategies as it prepares to submit its first BLA for afami-cel and expand its MAGE-A4 franchise.
The Phase 1 SURPASS trial presented by Adaptimmune Therapeutics (Nasdaq: ADAP) highlighted the efficacy of AKT inhibitors (AKTi) in enhancing SPEAR T-cell products. The addition of AKTi during ex vivo manufacturing improved T-cell proliferation and memory phenotype, leading to better antitumor responses. Notably, ADP-A2M4CD8 SPEAR T-cells displayed higher median persistence in patients, suggesting robust immune response potential. Results from the radiation sub-study indicated a disease control rate of 100%, underscoring the promising therapeutic effects of afami-cel.
Adaptimmune Therapeutics (ADAP) announced that its SPEARHEAD-1 trial has met its primary endpoint, with an overall response rate (ORR) of 34% in patients treated with afami-cel. This data will support a Biologics License Application (BLA) filing next year. The disease control rate stands at 85%, with a favorable benefit:risk profile observed. Translational data confirm afami-cel's efficacy against MAGE-A4 expressing targets both in vitro and in vivo.
Adaptimmune Therapeutics plc (ADAP) announced a strategic collaboration with Genentech, receiving a $150 million upfront payment. The SURPASS trial data presented at ESMO shows a 36% overall response rate and an 86% disease control rate across various solid tumors. The company has initiated the Phase 2 SURPASS-2 trial for esophageal and EGJ cancers and plans to begin SURPASS-3 for ovarian cancer in 2022. Financial results reveal a net loss of $42.4 million for Q3, while cash and liquidity are sufficient to fund operations into early 2024.
Deep Genomics has appointed Tal Zaks, MD, PhD, former CMO of Moderna, to its Strategic Advisory Board. Zaks brings valuable experience from leading mRNA vaccine development, including Moderna’s COVID-19 vaccine. This move aims to bolster Deep Genomics' mission to create programmable medicines through its advanced AI Workbench platform. With a recent $180 million funding, the company plans to expand its pipeline significantly, targeting thirty AI-discovered programs by 2024, while enhancing its research capabilities in Toronto and Cambridge.
Adaptimmune Therapeutics (Nasdaq:ADAP) plans to announce its third-quarter financial results for the period ending September 30, 2021, on November 4, 2021, prior to U.S. market opening. A live teleconference and webcast will follow at 8:00 a.m. EDT. The press release and webcast will be accessible via the investor section of the company’s website. Adaptimmune is focused on developing innovative cancer immunotherapy products using its unique SPEAR T-cell platform, targeting multiple solid tumors. This announcement comes with forward-looking statements regarding potential risks and uncertainties.
Adaptimmune Therapeutics (Nasdaq: ADAP) will present key clinical and translational data from its Phase 2 SPEARHEAD-1 trial at the CTOS meeting. This includes data crucial for their upcoming BLA submission for afami-cel targeting synovial sarcoma and MRCLS. They will also share findings from the Phase 1 SURPASS trial at the SITC meeting. Noteworthy presentations include an oral session by Dr. Brian Van Tine and a virtual symposium on November 11, 2021, emphasizing advancements in T-cell therapies.
Adaptimmune Therapeutics (NASDAQ: ADAP) announced promising outcomes from its Phase 1 SURPASS trial, demonstrating significant anti-tumor activity across various cancers. Key findings include a 36% overall response rate and an 86% disease control rate, with a complete response reported in ovarian cancer. The ADP-A2M4CD8 therapy has displayed enhanced tumor cell killing and improved immune system engagement. The company is actively recruiting patients for this and a new Phase 2 trial targeting esophageal and EGJ cancers, indicating progress towards late-stage development.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) has announced a strategic collaboration with Genentech to develop allogeneic cell therapies for cancer. This agreement entails an upfront payment of $150 million, with an additional $150 million expected over five years, and potential milestone payments exceeding $3 billion. Adaptimmune will utilize its induced pluripotent stem cell (iPSC) platform for T-cell production, while Genentech will focus on TCR input and clinical development. The partnership is subject to clearance under antitrust laws and aims to broaden personalized cancer treatment approaches.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) presented updated data from its Phase 1 ADP-A2AFP trial for liver cancer at the International Liver Cancer Association meeting. The trial showed a disease control rate of 64%, with one patient achieving a complete response and two patients maintaining stable disease for over 16 weeks. The safety profile was deemed acceptable, with no significant hepatotoxicity reported. The ongoing expansion phase aims to treat up to 25 patients, suggesting continued potential for this cell therapy approach in advanced hepatocellular carcinoma.
FAQ
What is the current stock price of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is the market cap of Adaptimmune Therapeutics plc American Depositary Shares (ADAP)?
What is Adaptimmune Therapeutics' primary focus?
What are the key programs of Adaptimmune Therapeutics?
What is afami-cel?
When is afami-cel expected to be commercially available?
What is lete-cel?
What are Adaptimmune’s recent strategic collaborations?
Where are Adaptimmune’s U.S. operations based?
What is Adaptimmune’s approach to cancer treatment?
What are the financial projections for Adaptimmune?
How can one get more information about Adaptimmune’s pipeline and operations?
